Lost In The Middle: Why Value Added Products Need Better Pricing Mechanisms
This article was originally published in Scrip
Europe needs better pricing systems for so-called value added medicines if the market for such products is to be sustainable or attractive, Warrick Smith, director general of the British Generic Manufacturers Association, the BGMA, told Scrip.
You may also be interested in...
Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.
More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.
The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.